HF-0299(HF-0299) - 药物靶点：IGF-1_在研适应症：神经痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

IGF-1

作用方式

刺激剂

作用机制

IGF-1刺激剂(胰岛素样生长因子-I刺激剂)

治疗领域

神经系统疾病其他疾病

在研适应症

神经痛

非在研适应症

痛经

原研机构

Deutsches Zentrum für Luft- und Raumfahrt e.V.

在研机构

Newron Pharmaceuticals SpA

Deutsches Zentrum für Luft- und Raumfahrt e.V.

非在研机构

Nobelpharma Co., Ltd.

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C19H26O3

InChIKeyWSCUHXPGYUMQEX-KCZNZURUSA-N

CAS号382-44-5

关联

2

项与 HF-0299 相关的临床试验

JPRN-JapicCTI-101118

/ Unknown status临床3期

Phase3,Randomized,Double-Blinded,Clinical Trial of NPC-01 for Treatment of Dysmenorrhea.

开始日期-

申办/合作机构

Nobelpharma Co., Ltd.

JPRN-jRCT2080221084

/ Unknown status临床3期

Phase3,Randomized,Double-Blinded,Clinical Trial of NPC-01 for Treatment of Dysmenorrhea.

开始日期2010-04-30

申办/合作机构

Nobelpharma Co., Ltd.

100 项与 HF-0299 相关的临床结果

登录后查看更多信息

100 项与 HF-0299 相关的转化医学

登录后查看更多信息

100 项与 HF-0299 相关的专利（医药）

登录后查看更多信息

809

项与 HF-0299 相关的文献（医药）

2025-02-01·Journal of Chromatography A

Magnetic molecularly imprinted polymers coupled with UPLC-MS/MS for simultaneous detection of 19 steroid hormones in human plasma

Article

作者: Cai, Susu ; Yu, Chunyi ; Kong, Xujing ; Li, Wenting ; Gao, Mengyao ; Li, Boyu ; Wei, Yun ; Chen, Baorong

Steroid hormones constitute a group of hormones with molecular weights ranging from 200 to 400 daltons, characterized by their highly similar chemical structures. Each hormone within this group holds significant value for the diagnosis of various diseases. Accurate clinical measurement of the levels of each hormone is crucial for the diagnosis in clinical settings. Due to the wide variety and different properties of steroid hormones in organisms, sample pretreatment is the rate-limiting step for analysis and detection. In this paper, magnetic molecule-imprinting polymers (MMIPs) were prepared by surface imprinting on silicon coated magnetic spheres, and a detection method of MMIPs-combined with liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for 19 steroid hormones in plasma was developed and verified. Fourier transform infrared spectroscopy, field emission scanning electron microscopy and transmission electron microscopy were used to confirm the formation of MMIPs materials, and the conditions of material synthesis and pretreatment of steroid hormones from plasma were optimized. The detection method was evaluated by using linearity, LOD and LOQ, precision, accuracy and matrix effect. The linearity of 19 steroid hormones was good, and the linear correlation coefficient was greater than 0.995. The coefficients of variation were 2.1-9.8 % and 1.1-9.7 % for intra-day and inter-day, respectively, and the recoveries were 83.6 %-118.2 % at low concentration, and the recoveries of medium and high concentrations were 94.6 %-113.8 % and 89.5 %-113.6 %, respectively. The coefficient of variation of Relative matrix effect of 19 steroid hormones measured in different batches of plasma was 2.1-5.4 % after isotope internal standard correction, which eliminated the influence of matrix effect.

2025-02-01·Aquaculture

Estradiol-17β but not 11β-hydroxyandrostenedione induces sex transdifferentiation in Siberian sturgeon

作者: Vizziano-Cantonnet, Denise ; Benech-Correa, German ; Benech-Correa, Germán ; Lasalle-Gerla, André ; Lasalle-Gerla, Andre

The Siberian sturgeon (Acipenser baerii) is a com.-important fish.As it is the females that produce the highly-prized caviar, genetic monosex cultures would be valuable.Before such populations can be produced, it will first be necessary to formally confirm whether this species has a ZZ/ZW sex-determination system.This discovery will in turn require the development of successful sex inversion and progeny testing approaches.This work is a first step in advancing this strategy.Our aim was to induce gonadal transdifferentiation using two steroids found naturally in fish -estradiol-17β (E2) and 11β-hydroxyandrostenedione (11β-And)- to feminize and masculinize genetic males and females, resp.Steroidal treatments were initiated at 3.5 mo of age, using 5μg/g body weight (b.w.) steroid injections; control fish received vehicle injections.Injections were given every 3 wk for 7 mo, concluding at 10.5 mo.Genetic and histol. tests were performed at 3.5, 6, 9, and 12 mo of age.All animals remained histol. undifferentiated at 3.5 mo.Control females showed signs of sex differentiation at 6 mo (columnar epithelium with distinct folds), and at 9 and 12 mo, control female and male gonads showed nests of oogonia and scattered spermatogonia, resp.The E2 treatment induced male-to-female gonad transdifferentiation in the genetically-sexed males at 6, 9, and 12 mo of age.In contrast, 11β-And failed to induce transdifferentiation of the female gonads.While some transient changes were observed, such as increased connective tissue between female germ cell clusters at 9 mo, the 12-mo-old fish displayed a normal female phenotype with no signs of sex inversion.Importantly, the exptl. E2 treatment produced live phenotypic females transdifferentiated from genetic males, with normal growth, feeding, and mobility as compared with control fish.Further experiments are needed to attempt masculinization of females, potentially with higher doses of natural androgens or other hormones and chems.

2024-10-01·Molecular and Cellular Endocrinology

Multiple androgen pathways contribute to the steroid signature of adrenarche

Article

作者: Jääskeläinen, Jarmo ; du Toit, Therina ; Voegel, Clarissa D ; Liimatta, Jani ; Lakka, Timo A ; Flück, Christa E

CONTEXTAdrenarche is a normal developmental event in mid-childhood characterized by increasing adrenal androgen secretion. The role of the classic androgen pathway has been well described in adrenarche, but the role of newer active androgens and additional androgen pathways is less clear.OBJECTIVETo study the contribution of novel androgens and related steroid biosynthesis pathways to the development of adrenarche, and to identify additional steroid biomarkers of adrenarche.DESIGNA longitudinal study of children aged 6-8 years at baseline, followed up at ages 8-10 and 14-16 years. A total of 34 children (20 girls) with clinical and/or biochemical signs of adrenarche (cases) and 24 children (11 girls) without these signs (controls) at age 8-10 years were included. Serum steroid profiling was performed by liquid chromatography high-resolution mass spectrometry.MAIN OUTCOME MEASURESThirty-two steroids compartmentalized in progestagens, gluco- and mineralocorticoid pathways, and four androgen related pathways, including the classic, backdoor, 11-oxy, and 11-oxy backdoor pathways.RESULTSThe classic and 11-oxy androgen pathways were more active, and serum concentrations of main androgens in the classic (dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione and androsterone) and 11-oxy (11β-hydroxyandrostenedione, 11β-hydroxytestosterone, 11-ketoandrostenedione, and 11-ketotestosterone) pathways were higher in cases at ages 6-8 and 8-10 years. Pregnenolone concentrations at adrenarchal age (8-10 years) and cortisol concentrations at adolescence (14-16 years) were higher in cases. 11β-hydroxyandrosterone and 11-ketoandrosterone tended to be higher in cases with clinical signs compared to cases who had only biochemical evidence of adrenarche, albeit they were detected at low levels. In biomarker analyses, calculated steroid ratios with cortisol, cortisone, or 11-deoxycortisone as dividers were better classifiers for adrenarche than single steroids. Among these ratios, androstenedione/cortisone was the best.CONCLUSIONSThe classic and 11-oxy androgen pathways are active in adrenarche. Children with earlier timing of adrenarche have higher serum cortisol levels at late pubertal age, suggesting that early adrenarche might have long-term effects on adrenal steroidogenesis by increasing the activity of the glucocorticoid pathway. Future studies should employ comprehensive steroid profiling to define novel classifiers and biomarkers for adrenarche and premature adrenarche.

100 项与 HF-0299 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经痛	临床1期	-	Newron Pharmaceuticals SpA	-
神经痛	临床1期	-	Deutsches Zentrum für Luft- und Raumfahrt e.V.	-
痛经	临床前	-	Nobelpharma Co., Ltd.	2009-05-01